We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+9%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$24.5B
AUM Growth
+$4.37B
Cap. Flow
+$2.47B
Cap. Flow %
10.08%
Top 10 Hldgs %
39.35%
Holding
397
New
164
Increased
36
Reduced
47
Closed
100

Sector Composition

Rank Sector Weight
1 Healthcare 29.35%
2 Financials 13%
3 Technology 12.06%
4 Communication Services 9.43%
5 Industrials 7.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XLRN
26
DELISTED
Acceleron Pharma
XLRN
$314M 1.28%
2,500,000
-100,000
-4% -$12.6M
CHTR icon
27
Charter Communications
CHTR
$18.5B
$307M 1.25%
425,901
-28,277
-6% -$19M
TRU icon
28
TransUnion
TRU
$15.2B
$306M 1.25%
2,782,782
-377,295
-12% -$39.3M
V icon
29
Visa
V
$684B
$292M 1.19%
1,249,404
-59,425
-5% -$13.6M
NYT icon
30
New York Times
NYT
$10.6B
$288M 1.18%
6,615,258
+4,235,636
+178% +$189M
NOW icon
31
ServiceNow
NOW
$119B
$287M 1.17%
+2,610,000
New +$265M
SHW icon
32
Sherwin-Williams
SHW
$88.8B
$285M 1.16%
1,045,168
-140,255
-12% -$38.4M
BX icon
33
Blackstone
BX
$107B
$284M 1.16%
2,921,736
-1,509,385
-34% -$134M
HLT icon
34
Hilton Worldwide
HLT
$72.7B
$277M 1.13%
2,300,077
+350,640
+18% +$43.8M
ELV icon
35
Elevance Health
ELV
$84B
$248M 1.01%
650,000
-175,000
-21% -$66.9M
AMRS
36
DELISTED
Amyris Inc.
AMRS
$215M 0.88%
13,110,000
-390,000
-3% -$5.82M
EXEL icon
37
Exelixis
EXEL
$13.6B
$200M 0.82%
11,000,000
+250,000
+2% +$5.83M
BEAM icon
38
Beam Therapeutics
BEAM
$2.82B
$193M 0.79%
1,500,000
+907,519
+153% +$72.3M
FATE icon
39
Fate Therapeutics
FATE
$296M
$165M 0.68%
1,905,000
+5,000
+0.3% +$403K
HWM icon
40
Howmet Aerospace
HWM
$117B
$162M 0.66%
4,702,479
+1,746,750
+59% +$58.3M
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$30.2B
$161M 0.66%
950,000
+250,000
+36% +$36.6M
BABA icon
42
Alibaba
BABA
$303B
$153M 0.63%
676,400
SJR
43
DELISTED
Shaw Communications Inc.
SJR
$146M 0.6%
+5,045,000
New +$146M
MRTX
44
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$145M 0.59%
900,000
+50,000
+6% +$8.03M
KSU
45
DELISTED
Kansas City Southern
KSU
$138M 0.56%
486,000
+246,000
+103% +$71M
IOVA icon
46
Iovance Biotherapeutics
IOVA
$2.66B
$137M 0.56%
5,250,000
+500,000
+11% +$13M
LU icon
47
Lufax Holding
LU
$1.27B
$128M 0.52%
2,831,100
+372,750
+15% +$18.8M
EFX icon
48
Equifax
EFX
$20.7B
$121M 0.49%
503,384
-103,245
-17% -$23.1M
COHR
49
DELISTED
Coherent Inc
COHR
$111M 0.45%
420,000
+295,000
+236% +$77.6M
QGEN icon
50
Qiagen
QGEN
$8.59B
$108M 0.44%
2,111,853
-282,021
-12% -$14.6M

Similar funds

Farallon Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Farallon Capital Management held 397 positions worth $24.5B, up 22% from $20.1B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Farallon Capital Management deployed $2.47B of net new capital in Q2 2021, opening 164 new positions and adding to 36 existing holdings. Its largest new stake was Nuance Communications, Inc.: 7,337,500 shares worth $399M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 35% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $456M trimmed.

  • Farallon Capital Management's largest Q2 2021 buy was Nuance Communications, Inc.: 7,337,500 shares worth $399M.
  • Farallon Capital Management added most to Alexion Pharmaceuticals in Q2 2021, an estimated $332M increase.
  • Farallon Capital Management's biggest Q2 2021 reduction was Alphabet (Google) Class C, cutting an estimated $456M.
  • Farallon Capital Management fully exited INPHI CORPORATION in Q2 2021, selling an estimated $311M.
  • Farallon Capital Management's ten largest holdings make up 39% of its $24.5B portfolio in Q2 2021.
  • Farallon Capital Management opened 164 new positions and closed 100 in Q2 2021.
  • Farallon Capital Management's portfolio value rose 22% quarter-over-quarter to $24.5B.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.